Itravozole 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole exerts its antifungal effect by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. This medication is indicated for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and other dermatophytic infections. Itravozole 200 Capsule is administered orally and demonstrates good bioavailability, with enhanced absorption when taken with food. It is metabolized primarily by the liver via the cytochrome P450 3A4 enzyme system, necessitating caution when co-administered with other drugs metabolized by this pathway to avoid potential drug interactions. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea, as well as headache and dizziness. Liver function should be monitored during prolonged therapy due to the risk of hepatotoxicity. Itravozole 200 Capsule should be used under medical supervision, with dosage adjustments based on the severity of infection and patient response. It is contraindicated in patients with known hypersensitivity to itraconazole or other azole antifungals.